The 4 IOL power formulas provided equivalent refractive results in the entire group of eyes and in the subsets of axial lengths tested.

When it can be used, interferometry is equivalent to immersion ultrasonography regarding biometric accuracy and precision. However, it cannot replace ultrasonography, especially for eyes with dense media opacity.

There are eight members of the herpesviridae family: herpes simplex virus-1 (HSV-1), HSV-2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, human herpes virus-6, human herpes virus-7 and human herpes virus-8. The diseases caused by viruses of the herpesviridae family are treated with and managed by systemic and topical antiviral therapies and immunomodulating drugs. Because these viruses establish a latent state in hosts, antiherpetic agents, such as nucleoside analogues, only control symptoms of disease or prevent outbreaks, and cannot cure the infections. There is a need for treatments that require less frequent dosing, can be taken even when lesions are more advanced than the first signs or symptoms, and can treat resistant strains of the viruses without the toxicities of existing therapies. Immunomodulating agents, such as resiquimod, can act on the viruses indirectly by inducing host production of cytokines, and can thereby reduce recurrences of herpes. The new helicase primase inhibitors, which are the first non-nucleoside antiviral compounds, are being investigated for treatment of HSV disease, including infections resistant to existing therapy.

Topical nonsteroidal anti-inflammatory agents have been associated with corneal ulceration and stromal melts. This is, to our knowledge, the first reported case involving the new agent, Nepafenac.

Uneventful small-incision cataract surgery was performed in a 70-year-old man and a 62-year-old woman with implantation of a Tecnis Z9000 intraocular lens (IOL) (Pharmacia). No ocular pathology was present in the patients preoperatively. Unsolicited complaints of negative dysphotopsia were made postoperatively, and the symptoms have persisted for more than 1 year in both patients. Symptomatic negative dysphotopsia may be seen in association with the Z9000 IOL.

Severe progressive epithelial ingrowth may be treated successfully with a combination of mechanical debridement, flap suturing, and fibrin glue application.

<h4>PURPOSE</h4><p>To assess the efficacy, predictability, and safety of LASIK for the surgical correction of low to moderate hyperopia and hyperopic astigmatism using the NIDEK EC-5000 excimer laser.</p> <h4>METHODS</h4><p>In a multicenter United States Food and Drug Administration (FDA) regulated study of LASIK, 7 centers enrolled 293 eyes with manifest refraction sphere that ranged from +0.50 to +6.00 diopters (D) with or without astigmatism up to 3.00 D. The intended outcome was plano in all eyes. Patients were treated bilaterally. One year postoperative outcomes are reported. </p> <h4>RESULTS</h4><p>The mean spherical equivalent refraction (MRSE) for all eyes changed from +2.61±1.19 D (range: +0.50 to +6.63 D) preoperatively to +0.35±0.54 D (range: -1.63 to +2.00 D) 1 year postoperatively. Overall, 61% (170/279) of eyes achieved distance uncorrected visual acuity (UCVA) of 20/20 or better, 82% (228/279) of eyes saw 20/25 or better, and 99% (277/279) of eyes saw 20/40 or better. Refractive accuracy was demonstrated as 63.1% (176/279) of eyes achieved a MRSE within ±0.50 D and 90.3% (252/279) of eyes within ±1.00 D. Less than 2% (4/279) of eyes lost 2 lines of distance best spectacle-corrected visual acuity. Stability of refraction was demonstrated by 6 months, with a mean hyperopic shift of <0.03 D from 3 to 6 months. </p> <h4>CONCLUSIONS</h4><p>The NIDEK EC-5000 corrected hyperopia and hyperopic astigmatism with UCVA, refractive accuracy, 1-year stability, and safety that surpassed all FDA criteria. [<cite>J Refract Surg.</cite> 2008;24:123-136.]</p> <h4>ABOUT THE AUTHORS</h4> <p>From InView, Atlanta, Ga (Waring); Clinical Research Consultants Inc, Cincinnati, Ohio (Fant); Sound Eye and Laser, Seattle, Wash (Phillips); Fischer Laser Eye Center, Willmar, Minn (Fischer); Liberty Laser Eye Center, Vienna, Va (Tanchel); Southern Eye Associates, Memphis, Tenn (Schanzer); the Department of Ophthalmology, Loma Linda University, Loma Linda, Calif (Narvaez); and CODET/Aris Vision Institute, Tijuana, BC, Mexico (Chayet).</p> <p>Dr Waring is a consultant for NIDEK, AMO, Acufocus, Calhoun Vision, and SCHWIND. Dr Chayet is a consultant for NIDEK and Calhoun Vision. Dr Fant is a consultant for NIDEK and has a financial interest in Clinical Research Consultants Inc. The remaining authors have no financial interest in the materials presented herein.</p> <p>Correspondence: George O. Waring III, MD, InView, 301 Perimeter Center North, Ste 600, Atlanta, GA 30346. Tel: 678.222.5102; Fax: 404.250.9006; E-mail: <a href="mailto:drgeorge@georgewaring.com">drgeorge@georgewaring.com</a></p> <p>Received: June 25, 2007</p> <p>Accepted: December 4, 2007</p>

Significant changes in cyclotorsion and centroid shifts were noted prior to surgery as well as intraoperatively with both LASIK and PRK. It may be advantageous to engage iris registration immediately prior to ablation to provide a reference point representative of eye position at the initiation of laser delivery.